---
layout: archive
title: "Research Experiences"
permalink: /talks/
author_profile: true
---

<div style="text-align: justify; line-height: 1.8; font-family: Arial, sans-serif;">


  <!-- Project 1 -->
  <div style="margin-bottom: 40px;">
    <strong>1. Mendelian Randomization Analysis of Multiregional Psychiatric Disorders</strong> (Completed)<br>
    <span style="font-size: 0.9rem; color: #666;">- Jun. 2025 – Aug. 2025</span><br>
    <span style="font-size: 0.9rem; color: #666;">- Research assistant</span><br>
    <span style="font-size: 0.9rem; color: #666;">- Supervisor: Dr. <a href="https://orcid.org/0000-0002-5062-7843">Weijie Xie</a></span><br>
    <span style="font-size: 0.9rem; color: #666;">- Shanghai Mental Health Center; Shanghai Pudong New Area Mental Health Center, Tongji University School of Medicine, Shanghai, China</span>  
    
    <div style="margin: 15px 0;">
      <strong>Description:</strong><br>
      <strong>Psychiatric disorders</strong> including depression, anxiety, and addiction represent a major global health burden and frequently co-occur. Their comorbidity may be driven by shared biological mechanisms, for instance, neurotransmitter dysregulation and <strong>inflammatory processes</strong>.  However, the shared <strong>genetic variants</strong> underlying these disorders remain unclear.
    </div>
    
    <div style="margin: 15px 0;">
      In this project, we integrated publicly available genome-wide association study (GWAS) data with <strong>Mendelian Randomization (MR)</strong> , <strong>Transcriptome-Wide and Proteome-Wide Association Studies (TWAS/PWAS)</strong>, and <strong>Bayesian Colocalization</strong> to elucidate genetically driven causal mechanisms. 
    </div>
    <div style="margin: 15px 0;">
      We constructed a cross-disorder genetic map identifying <strong>pleiotropic risk loci</strong> and prioritizing <strong>candidate genes</strong> with trans-diagnostic therapeutic potential. This approach provides causal evidence to inform interventions for psychiatric conditions.
    </div>
    
    <div style="text-align: center; margin: 20px 0;">
      <img src='/files/multi_psychiatry_2.png' alt="Cross-brain-region distribution" style="width: 70%; border: 1px solid #ddd; border-radius: 5px;">
      <div style="font-size: 0.8rem; color: #888; margin-top: 5px;">Cross-brain-region distribution of genetic risk for psychiatric disorders<br> 
        (Integrating TWAS and Bayesian colocalization analysis).
      </div>
    </div>
  </div>

  <!-- Project 2 -->
  <div style="margin-bottom: 40px; border-top: 1px solid #eee; padding-top: 20px;">
    <strong>2. Comprehensive Single-cell Analysis of Microglia in Major Depressive Disorder</strong> (Completed)<br>
    <span style="font-size: 0.9rem; color: #666;">- Aug. 2024 – May. 2025</span><br>
    <span style="font-size: 0.9rem; color: #666;">- Research assistant</span><br> 
    <span style="font-size: 0.9rem; color: #666;">- Supervisor: Dr. <a href="https://orcid.org/0000-0002-5062-7843">Weijie Xie</a></span><br>
    <span style="font-size: 0.9rem; color: #666;">- Shanghai Mental Health Center; Shanghai Pudong New Area Mental Health Center, Tongji University School of Medicine, Shanghai, China</span>
      
    <div style="margin: 15px 0;">
      <strong>Description:</strong><br>
      <strong>Major depressive disorder (MDD)</strong> is closely associated with <strong>neuroimmune dysfunction</strong>, though the specific mechanisms regulating <strong>microglia-GABAergic neuron communication</strong> remain unclear. 
    
    <div style="margin: 15px 0;">  
      Using <strong>single-nucleus RNA sequencing data</strong> from MDD patients and healthy controls (sourced from GEO), we characterized <strong>microglial heterogeneity</strong> and cell-cell communication networks. We employed a stack of <strong>69 machine learning models</strong> to identify and prioritize key genes, followed by <strong>MR</strong> to infer causal relationships between microglial features and MDD risk.
    </div>
    
    <div style="margin: 15px 0;">
      Our results revealed that <strong>dysregulated microglia</strong> subtypes—driven by <strong>metabolic imbalance</strong> and <strong>chronic neuroinflammation</strong>—disrupt communication with GABAergic neurons in MDD, highlighting novel potential therapeutic targets for restoring neuroimmune homeostasis in MDD.
    </div>
    
    <div style="text-align: center; margin: 20px 0;">
      <img src='/files/个人网站-MG.png' alt="Simplified Workflow" style="width: 70%; border: 1px solid #ddd; border-radius: 5px;">
      <div style="font-size: 0.8em; color: #888; margin-top: 5px;">The simplified workflow.</div>
    </div>
  </div>

  <!-- Project 3 -->
  <div style="margin-bottom: 40px; border-top: 1px solid #eee; padding-top: 20px;">
    <strong>3. Immune Mechanisms of the Comorbidity of SLE and MDD</strong> (In progress)<br>
    <span style="font-size: 0.9rem; color: #666;">- Jul. 2023 – Present</span><br>
    <span style="font-size: 0.9rem; color: #666;">- Research assistant</span><br>
    <span style="font-size: 0.9rem; color: #666;">- Supervisor: Dr. Jiaoqiong Guan</span><br>
    <span style="font-size: 0.9rem; color: #666;">- Shanghai Mental Health Center, Shanghai, China</span>
    
    <div style="margin: 15px 0;">
      <strong>Description:</strong><br>
      Patients with Systemic Lupus Erythematosus (SLE) exhibit a heightened risk of developing MDD, yet the <strong>shared immunopathological mechanisms</strong> driving this comorbidity are poorly defined.
    </div>
    
    <div style="margin: 15px 0;"> 
      We analyzed SLE-MDD transcriptomic datasets from GEO using <strong>Weighted Gene Co-Expression Network Analysis (WGCNA)</strong> and differential gene expression analysis to identify co-expression modules. A ensemble of <strong>101 machine learning models</strong> was applied to select hub genes and construct diagnostic predictors. Subsequent immune infiltration and functional enrichment analyses were performed, and candidate biomarkers were validated using external <strong>single-cell RNA-seq data</strong>, <strong>immunohistochemistry</strong>, and <strong>Western blot</strong>.
    
    <div style="margin: 15px 0;">
      <strong>A novel immune-related target</strong> was identified, which may mediate the comorbidity of SLE-MDD progression via modulation of <strong>T-cell function and abundance</strong>. Targeting this pathway could offer a dual-benefit therapeutic strategy for attenuating the progression of both conditions.
    </div>
    
    <div style="text-align: center; margin: 20px 0;">
      <img src='/files/3D-SLE.png' alt="3D Visualization" style="width: 70%; border: 1px solid #ddd; border-radius: 5px;">
      <div style="font-size: 0.8rem; color: #888; margin-top: 5px;">3D visualization of single-cell data using Scatterplot3d package.</div>
    </div>
  </div>

  <!-- Project 4 -->
  <div style="margin-bottom: 40px; border-top: 1px solid #eee; padding-top: 20px;">
    <strong>4. Microglia-Driven Lysosomal Mechanisms in the Alleviation of Depressive-like Behaviors</strong> (In progress)<br>
    <span style="font-size: 0.9rem; color: #666;">- Sep. 2020 – Jul. 2023</span><br>
    <span style="font-size: 0.9rem; color: #666;">- Master’s Student Researcher</span><br>
    <span style="font-size: 0.9rem; color: #666;">- Supervisor: Prof. Dr. <a href="https://orcid.org/0000-0003-1875-5463">Wuyang Wang</a></span><br>
    <span style="font-size: 0.9rem; color: #666;">- Xuzhou Medical University, Department of Anesthesiology, Xuzhou, Jiangsu Province, China</span>
    
    <div style="margin: 15px 0;">
      <strong>Description:</strong><br>
      <strong>MDD</strong> is a complex psychiatric condition characterized by persistent low mood and anhedonia. <strong>Neuroinflammation</strong>, driven largely by microglial activation, plays a critical role in its pathogenesis, contributing to synaptic dysfunction, neuronal damage, and impaired neural connectivity.
    </div>
    
    <div style="margin: 15px 0;">
      Our lab is interested in the function of microglia lysosomes in the pathology of MDD. This project investigated the role of <strong>microglial lysosomal pathways</strong> in MDD. Experimental models included <strong>chronic restraint stress</strong>, <strong>LPS-induced neuroinflammation</strong> (via intracerebroventricular injection), and <strong>genetic knockout mice</strong>. A suite of techniques was employed: <strong>primary microglia extraction and culture</strong>, behavioral analyses, Western blot, qPCR, ELISA, immunofluorescence, Golgi-Cox staining, <strong>3D reconstruction (Imaris)</strong>, and <strong>bioinformatic analyses (R)</strong>.
    </div> 
    
    <div style="margin: 15px 0;">
      We identified a novel microglial lysosomal mechanism that significantly influences depressive-like behaviors. Based on these findings, we proposed a targeted therapeutic strategy aimed at modulating this pathway, offering a potential new avenue for the treatment of MDD.
    </div>
    
    <div style="text-align: center; margin: 20px 0;">
      <img src='/images/research6.png' alt="Microglia Morphology" style="width: 70%; border: 1px solid #ddd; border-radius: 5px;">
      <div style="font-size: 0.8rem; color: #888; margin-top: 5px;">
        Microglia in the LPS group exhibited enlarged cell bodies and shortened processes, indicative of an activated state. Conversely, treatment with our drug induced microglial morphology resembling a resting state.
      </div>
    </div>
  </div>

</div>
